Stock listing
Helsinki:HRTIS Herantis Pharma PLC Osake
Home listing (Helsinki) of Herantis Pharma PLC
Follow Herantis Pharma PLC into a list and get an email when it puts out news.
Share price · OMXHEX:HRTIS
€1.33 EUR -0.07 (-5.0%)
Close on Nov 20, 2026
- Day range
- €1.30 – €1.50 EURNov 20, 2026
- Volume
- 26,041 sharesNov 20, 2026
- Market cap
- €35.25M EURAt the close on Nov 20, 2026 · price × 26.50M shares outstanding
- 52-week range
- €1.05 – €2.87 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €40,800 EURMedian day 24,607 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Helsinki:HRTIS · Home | €1.33 EUR | -0.07 (-5.0%) | 26,041 | €1.49 | €1.50 | €1.302 | €1.40 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OMXHEX:HRTIS · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €1.33 | -0.07 | -5.0% | €1.49 | €1.50 | €1.302 | 26,041 | |
| €1.40 | +0.05 | +3.7% | €1.388 | €1.40 | €1.362 | 24,623 | |
| €1.35 | 0.00 | 0.0% | €1.362 | €1.398 | €1.334 | 21,758 | |
| €1.35 | +0.08 | +6.3% | €1.272 | €1.388 | €1.272 | 52,123 | |
| €1.27 | +0.052 | +4.3% | €1.216 | €1.31 | €1.15 | 45,581 | |
| €1.218 | -0.072 | -5.6% | €1.288 | €1.294 | €1.216 | 37,522 | |
| €1.29 | +0.172 | +15.4% | €1.138 | €1.30 | €1.138 | 127,908 | |
| €1.118 | -0.016 | -1.4% | €1.13 | €1.134 | €1.05 | 54,381 | |
| €1.134 | -0.034 | -2.9% | €1.162 | €1.184 | €1.13 | 27,065 | |
| €1.168 | -0.008 | -0.7% | €1.194 | €1.194 | €1.11 | 25,839 | |
| €1.176 | -0.01 | -0.8% | €1.188 | €1.26 | €1.16 | 9,414 | |
| €1.186 | +0.006 | +0.5% | €1.198 | €1.206 | €1.154 | 16,432 | |
| €1.18 | -0.02 | -1.7% | €1.20 | €1.20 | €1.118 | 64,380 | |
| €1.20 | -0.034 | -2.8% | €1.29 | €1.29 | €1.17 | 27,832 | |
| €1.234 | -0.046 | -3.6% | €1.26 | €1.26 | €1.234 | 11,527 | |
| €1.28 | +0.114 | +9.8% | €1.158 | €1.28 | €1.158 | 41,785 | |
| €1.166 | +0.016 | +1.4% | €1.138 | €1.174 | €1.13 | 99,545 | |
| €1.15 | -0.076 | -6.2% | €1.25 | €1.25 | €1.132 | 50,997 | |
| €1.226 | -0.024 | -1.9% | €1.248 | €1.248 | €1.21 | 19,388 | |
| €1.25 | -0.016 | -1.3% | €1.268 | €1.27 | €1.25 | 13,091 | |
| €1.266 | -0.014 | -1.1% | €1.33 | €1.33 | €1.25 | 19,683 | |
| €1.28 | -0.016 | -1.2% | €1.36 | €1.36 | €1.27 | 14,249 | |
| €1.296 | -0.002 | -0.2% | €1.296 | €1.298 | €1.27 | 21,910 | |
| €1.298 | -0.062 | -4.6% | €1.358 | €1.358 | €1.274 | 37,796 | |
| €1.36 | +0.014 | +1.0% | €1.36 | €1.37 | €1.342 | 11,360 | |
| €1.346 | -0.016 | -1.2% | €1.362 | €1.37 | €1.316 | 34,236 | |
| €1.362 | +0.02 | +1.5% | €1.342 | €1.362 | €1.338 | 29,786 | |
| €1.342 | +0.004 | +0.3% | €1.35 | €1.362 | €1.328 | 12,773 | |
| €1.338 | -0.006 | -0.4% | €1.42 | €1.42 | €1.33 | 11,667 | |
| €1.344 | -0.056 | -4.0% | €1.41 | €1.42 | €1.344 | 11,859 | |
| €1.40 | +0.03 | +2.2% | €1.372 | €1.40 | €1.342 | 29,524 | |
| €1.37 | -0.048 | -3.4% | €1.36 | €1.37 | €1.32 | 41,046 | |
| €1.418 | +0.026 | +1.9% | €1.392 | €1.428 | €1.342 | 16,567 | |
| €1.392 | -0.03 | -2.1% | €1.422 | €1.422 | €1.358 | 19,043 | |
| €1.422 | +0.016 | +1.1% | €1.38 | €1.428 | €1.37 | 13,202 | |
| €1.406 | -0.02 | -1.4% | €1.45 | €1.45 | €1.382 | 11,750 | |
| €1.426 | +0.026 | +1.9% | €1.40 | €1.448 | €1.372 | 24,626 | |
| €1.40 | 0.00 | 0.0% | €1.398 | €1.422 | €1.354 | 26,860 | |
| €1.40 | +0.008 | +0.6% | €1.398 | €1.40 | €1.35 | 21,722 | |
| €1.392 | -0.008 | -0.6% | €1.40 | €1.40 | €1.372 | 21,941 | |
| €1.40 | +0.01 | +0.7% | €1.404 | €1.41 | €1.394 | 7,175 | |
| €1.39 | -0.01 | -0.7% | €1.40 | €1.416 | €1.384 | 18,696 | |
| €1.40 | +0.012 | +0.9% | €1.392 | €1.41 | €1.38 | 48,462 | |
| €1.388 | -0.022 | -1.6% | €1.412 | €1.428 | €1.384 | 34,905 | |
| €1.41 | 0.00 | 0.0% | €1.412 | €1.412 | €1.38 | 18,974 | |
| €1.41 | -0.02 | -1.4% | €1.43 | €1.43 | €1.40 | 60,102 | |
| €1.43 | -0.038 | -2.6% | €1.458 | €1.462 | €1.422 | 32,111 | |
| €1.468 | -0.01 | -0.7% | €1.51 | €1.51 | €1.454 | 14,196 | |
| €1.478 | -0.022 | -1.5% | €1.50 | €1.522 | €1.456 | 31,157 | |
| €1.50 | -0.03 | -2.0% | €1.53 | €1.544 | €1.46 | 60,971 | |
| €1.53 | -0.03 | -1.9% | €1.56 | €1.582 | €1.524 | 25,220 | |
| €1.56 | -0.036 | -2.3% | €1.596 | €1.596 | €1.54 | 26,407 | |
| €1.596 | +0.036 | +2.3% | €1.56 | €1.598 | €1.546 | 6,903 | |
| €1.56 | -0.002 | -0.1% | €1.564 | €1.59 | €1.542 | 12,308 | |
| €1.562 | -0.026 | -1.6% | €1.57 | €1.586 | €1.54 | 19,023 | |
| €1.588 | -0.048 | -2.9% | €1.618 | €1.634 | €1.554 | 13,973 | |
| €1.636 | -0.014 | -0.8% | €1.65 | €1.66 | €1.622 | 11,966 | |
| €1.65 | +0.03 | +1.9% | €1.658 | €1.696 | €1.648 | 20,408 | |
| €1.62 | 0.00 | 0.0% | €1.638 | €1.68 | €1.62 | 12,313 | |
| €1.62 | -0.07 | -4.1% | €1.66 | €1.682 | €1.606 | 24,590 | |
| €1.69 | +0.052 | +3.2% | €1.652 | €1.69 | €1.652 | 10,781 | |
| €1.638 | +0.106 | +6.9% | €1.56 | €1.64 | €1.56 | 27,497 | |
| €1.532 | +0.002 | +0.1% | €1.592 | €1.626 | €1.532 | 66,285 | |
| €1.53 | -0.16 | -9.5% | €1.678 | €1.678 | €1.526 | 87,493 |
Splits
1 split · OMXHEX:HRTIS · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 102-for-97 | Split |
- Ticker
- Helsinki:HRTIS
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Helsinki
- Currency
- EUR
What changed lately
Latest news release · Aug 10, 2026
Herantis Pharma Oyj to publish financial statements for the first half of 2026 on August 20, 2026 – invitation to webcast presentation
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 22 slides
Latest news
Herantis Pharma Oyj to publish financial statements for the first half of 2026 on August 20, 2026 – invitation to webcast presentation
Aug 10, 2026
Closed €1.71 (+5.0%) on Aug 10, 2026
Herantis appoints experienced drug development expert Dr Juha Savola as Chief Medical Officer
Jun 25, 2026
Closed €1.87 (+0.2%) on Jun 25, 2026
Herantis reports positive FDA feedback and finalizes Phase 2a study design for HER-096
Jun 2, 2026
Closed €2.27 (+2.0%) on Jun 2, 2026
Plc Annual Report 2025
Mar 30, 2026
Closed €1.62 (-2.1%) on Mar 30, 2026
Herantis Pharma to present HER-096 Phase 1b data at International Conference on Alzheimer’s & Parkinson’s Diseases
Mar 16, 2026
Closed €1.90 (+2.7%) on Mar 16, 2026
Herantis Pharma releases 2H and FY 2025 report today
Mar 5, 2026
Closed €2.03 (-2.4%) on Mar 5, 2026
Herantis Pharma Oyj to publish financial statements 2025 on 5 March 2026 – invitation to webcast presentation
Feb 23, 2026
Closed €2.15 (-0.5%) on Feb 23, 2026
Inside information: Herantis Pharma selected for Horizon 2025 grant of EUR 8.0 million for Phase 2 trial of HER-096
Feb 19, 2026
Closed €2.16 (-0.5%) on Feb 20, 2026
Herantis Pharma - Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson's disease
Jan 7, 2026
Closed €2.55 (+5.8%) on Jan 8, 2026
Herantis Pharma announces successful completion of six-month GLP toxicology study of HER-096
Nov 26, 2025
Closed €2.17 (+2.4%) on Nov 26, 2025
Herantis Pharma PLC on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 11 in the last 12 months · 17 in all · newest Aug 10, 2026 · oldest 2025
- Decks
- 33 decks · latest September 2026
Where Herantis Pharma PLC is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Helsinki:HRTIS · Home listing · This page | Helsinki | Finland | EUR |
| LS Exchange:A1158V | LS Exchange | Germany | EUR |
| Lang & Schwarz:A1158V | Lang & Schwarz | Germany | EUR |
Valuation
Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- €35.19M EUR
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Herantis Pharma PLC · OMXHEX:HRTIS | US$38.69M | US$38.62M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Dogwood Therapeutics, Inc. · NASDAQ:DWTX | US$39.57M | US$34.74M | n/a | 347× | n/a | 0.6× | n/a | 0.0× | 0.79 |
| Quratis Inc. · KRX:348080 | US$38.60M | US$29.66M | n/a | 36.2× | n/a | 1.1× | n/a | 0.0× | n/a |
| Harvard Apparatus Regenerative Technology Inc · OTC:HRGN | US$38.54M | US$36.69M | n/a | 36.5× | n/a | 73.8× | −642.0% | 0.0× | 0.09 |
| KoBioLabs, Inc. · KRX:348150 | US$38.47M | US$7.00M | n/a | 0.1× | n/a | 1.8× | −6.4% | 0.2× | n/a |
| OSE Immunotherapeutics SA · EURONEXT:OSE | US$38.31M | US$52.28M | n/a | 18.2× | n/a | 1.3× | n/a | 1.3× | n/a |
| Sprint Bioscience AB · OMXSTO:SPRINT | US$37.98M | US$28.86M | 5.1× | 2.1× | 3.7× | 4.3× | 54.4% | 0.0× | n/a |
| Theralase Technologies Inc. · TSXV:TLT | US$37.89M | US$34.22M | n/a | 61.1× | n/a | 7.9× | −472.5% | 0.0× | 0.75 |
| Connect Biopharma Holdings Limited · NASDAQ:CNTB | US$37.15M | US$18.16M | n/a | 4.9× | n/a | 3.1× | n/a | 0.0× | 0.93 |
| Coiled Therapeutics PLC · LSE:COIL | US$37.13M | US$30.46M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | n/a |
| TaiRx, Inc. · TPEX:6580 | US$37.08M | US$28.62M | n/a | 33.8× | n/a | 3.3× | −793.3% | 0.0× | n/a |
| Median of the others | US$38.14M | US$30.06M | 5.1× | 33.8× | 3.7× | 2.4× | −472.5% | 0.0× | 0.77 |
Forecasts
Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.
- Price target
- 2.00 EUR · Analysts' mean
- EPS, year to Dec 2026
- -0.16 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Antti Vuolanto | Chief Executive Officer |
| Tone Kvåle | Chief Financial Officer |
| Henri Huttunen | Chief Scientific Officer |
| Juha Savola | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Timo Veromaa | MD, PhD, eMBA, Chairman of the Board |
| Aki Prihti | Board member |
| Frans Wuite | MD, MBA, Board Member |
| Hilde Furberg | MSc, Board Member |
| Mats Thorén | Board member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q4 2022 | Mar 2, 2023 · Before open | +1.5% |
| Q2 2022 | Aug 25, 2022 | −9.3% |
| Q4 2021 | Mar 7, 2022 | −2.4% |
| Q2 2021 | Aug 26, 2021 · Before open | −6.2% |
| Q4 2020 | Mar 3, 2021 · Before open | −0.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 22 slides | September 2026 |
| Investor Presentation (June 2026) | Investor deck | 31 slides | June 2026 |
| Investor Presentation (October 2024) | Investor deck | 24 slides | October 2024 |
| FY2023 Earnings Presentation | Earnings | 17 slides | Mar 6, 2024 |
| Technical Presentation (October 2023) | Technical | 16 slides | Oct 25, 2023 |
| Investor Presentation (September 2023) | Investor deck | 14 slides | September 2023 |
| Investor Presentation (January 2023) | Investor deck | 12 slides | Jan 26, 2023 |
| Investor Presentation (May 2022) | Investor deck | 17 slides | May 2022 |
| Investor Presentation (May 2022) | Investor deck | 17 slides | May 2022 |
| Investor Presentation (May 2022) | Investor deck | 17 slides | May 2022 |
All 33 decks
Financials
Annual, in EUR
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 25.3K |
| Cost of revenue | 927.7K | 1.05M | 1.20M | 1.22M | 27.1K | |||||
| Gross profit | -928.0K | -1.05M | -1.20M | -1.22M | -1.80K | |||||
| Research and development | 3.60M | 2.70M | 5.00M | 6.20M | 5.33M | 4.93M | 2.10M | 2.33M | 2.73M | |
| Selling, general and administrative | 1.92M | 1.49M | 1.74M | 2.65M | 2.25M | 2.04M | 1.40M | 1.24M | 1.02M | 0 |
| Operating income | -6.39M | -5.03M | 154.4K | -7.99M | -9.05M | -8.07M | -7.16M | -4.87M | -2.24M | -4.42M |
| Depreciation and amortization | 5.03M | 0 | 159.7K | 2.72M | 927.7K | 1.05M | 1.20M | 1.22M | 1.20M | |
| EBITDA | 489 | 154.4K | -7.83M | -6.33M | -7.14M | -6.11M | -3.67M | -1.02M | -3.22M | |
| Interest expense | 13.7K | 5.66K | 551.6K | 1.33M | 63.0K | 1.08M | 868.8K | 60.6K | 309.2K | 82.5K |
| Income before tax | -6.62M | -4.94M | 279.8K | -9.32M | -23.6M | -9.15M | -8.01M | -4.18M | -2.17M | -4.42M |
| Income tax | -1 | 1.33M | 308.4K | 1.08M | 868.8K | -2 | 59.5K | 78.2K | ||
| Net income | -6.62M | -4.94M | 279.8K | -9.32M | -23.6M | -9.15M | -8.01M | -4.18M | -2.17M | -4.42M |
| Earnings per share, basic | -0.28 | -0.24 | 0.02 | -0.64 | -2.31 | -1.18 | -1.30 | -0.85 | -0.51 | -1.02 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 751.0K | 635.0K | 5.50M | 5.04M | 5.63M | 12.3M | 6.01M | 719.1K | 90.6K | 782.2K |
| Short-term investments | 1.85M | 1.50M | 985.2K | 955.0K | 985.2K | 985.2K | 985.2K | 1.47M | 5.31M | 2.05M |
| Receivables | 72.0K | 406.5K | 257.4K | 241.3K | 142.7K | 174.3K | 261.8K | 93.7K | 90.5K | 41.6K |
| Current assets | 2.67M | 2.57M | 6.75M | 6.23M | 6.76M | 13.5M | 7.26M | 2.29M | 5.51M | 2.89M |
| Property, plant and equipment | 0 | 0 | 0 | 3.69K | 4.92K | 6.56K | 8.75K | |||
| Goodwill | 0 | 77.7K | 310.9K | 544.0K | ||||||
| Total assets | 2.67M | 2.57M | 6.75M | 6.23M | 6.92M | 16.4M | 11.1M | 7.15M | 11.6M | 10.2M |
| Accounts payable | 389.0K | 278.0K | 748.7K | 660.3K | 788.0K | 716.1K | 1.62M | 199.6K | 278.3K | 186.1K |
| Current liabilities | 912.0K | 634.0K | 1.99M | 1.90M | 1.89M | 2.89M | 2.01M | 1.36M | 1.46M | 613.0K |
| Long-term debt | 20.0K | 2.18M | 29.8K | 4.39M | 6.29M | 5.94M | 7.21M | 5.88M | 6.02M | 8.02M |
| Total debt | 3.45M | 30.0K | 34.8K | 4.54M | 4.69M | 7.21M | 7.21M | 6.39M | 6.57M | 8.12M |
| Total liabilities | 4.36M | 2.81M | 2.02M | 6.29M | 6.36M | 8.83M | 9.22M | 7.24M | 7.48M | 8.63M |
| Shareholders' equity | -1.69M | -243.0K | 4.73M | -60.3K | 554.3K | 7.59M | 1.85M | -89.3K | 4.09M | 1.57M |
| Shares outstanding | 23.6M | 20.2M | 17.2M | 14.7M | 10.2M | 7.77M | 6.14M | 4.92M | 4.22M | 4.33M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -6.10M | -6.54M | -4.64M | -8.94M | -9.93M | -8.56M | -5.96M | -3.73M | -2.60M | -3.04M |
| Capital spending | -6.10M | 0 | -4 | 0 | 0 | 0 | 0 | 0 | 0 | -10.4K |
| Free cash flow | -6.10M | -6.54M | -4.64M | -8.94M | -9.93M | -8.56M | -5.96M | -3.73M | -2.60M | -3.05M |
| Cash from investing | -244.0K | -474.0K | 607.1K | -210.1K | -1.05M | 3.69K | 3.69K | 7.17K | -33 | -71.3K |
| Cash from financing | 6.46M | 2.15M | 4.50M | 8.56M | 4.03M | 14.9M | 10.8M | 508.6K | 5.17M | 395.9K |
| Share buybacks | 5.19M | 0 | 4.51M | 8.71M | 4.04M | 14.9M | ||||
| Change in cash | 116.5K | -4.87M | 467.2K | -594.6K | -5.90M | 6.33M | 4.81M | -3.22M | 2.57M | -2.71M |
Cap table
Built by 6ix from Herantis Pharma PLC’s releases
- Common shares
- 26,503,817
- Fully diluted
- 26,503,817
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 26,503,817 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 26,503,817 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Aki Prihti | Board member · Since at least Mar 30, 2026 |
| Antti Vuolanto | Chief Executive Officer · Since at least Aug 10, 2026 |
| Frans Wuite | MD, MBA, Board Member · Since at least Mar 30, 2026 |
| Henri Huttunen | Chief Scientific Officer · Since at least Mar 30, 2026 |
| Hilde Furberg | MSc, Board Member · Since at least Mar 30, 2026 |
| Juha Savola | Chief Medical Officer · Since at least Aug 10, 2026 |
| Mats Thorén | Board member · Since at least Mar 30, 2026 |
| Timo Veromaa | MD, PhD, eMBA, Chairman of the Board · Since at least Mar 30, 2026 |
| Tone Kvåle | Chief Financial Officer · Since at least Aug 10, 2026 |
Log in to ask 6ix AI your own questions about Herantis Pharma PLC.